Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Kidney transplantation under FK 506.

Starzl, TE and Fung, J and Jordan, M and Shapiro, R and Tzakis, A and McCauley, J and Johnston, J and Iwaki, Y and Jain, A and Alessiani, M (1990) Kidney transplantation under FK 506. JAMA, 264 (1). 63 - 67. ISSN 0098-7484

Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Starzl, TEtes11@pitt.eduTES11
Fung, J
Jordan, M
Shapiro, R
Tzakis, A
McCauley, J
Johnston, J
Iwaki, Y
Jain, A
Alessiani, M
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 4 July 1990
Date Type: Publication
Journal or Publication Title: JAMA
Volume: 264
Number: 1
Page Range: 63 - 67
Institution: University of Pittsburgh
Refereed: Yes
Uncontrolled Keywords: Adult, Anti-Bacterial Agents, Child, Female, Follow-Up Studies, Graft Rejection, Humans, Immunosuppressive Agents, Infections, Kidney Failure, Chronic, Kidney Transplantation, Male, Middle Aged, Tacrolimus, Tissue Donors
ISSN: 0098-7484
Funders: NIDDK NIH HHS (R01 DK029961-19), NIDDK NIH HHS (DK 29961)
Other ID: uls-drl:31735062116508, Starzl CV No. 1096
Date Deposited: 08 Apr 2010 17:18
Last Modified: 17 Dec 2019 16:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item